Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
C 1.23 3.36% 0.04
NKTR closed up 3.36 percent on Friday, November 1, 2024, on 78 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 5
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 3.36%
New Downtrend Bearish 3.36%
NR7 Range Contraction 3.36%
Stochastic Reached Oversold Weakness 3.36%
BB Squeeze Ended Range Expansion 3.36%
Below Lower BB Weakness 3.36%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 18 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Rose Above Previous Day's High about 18 hours ago
Up 5% about 18 hours ago
Rose Above Lower Bollinger Band about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Nektar Therapeutics Description

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmaceutical Immunology Pain Drugs Clinical Development Breast Cancer Pharmacology Antibiotics Opioids Ovarian Cancer Chronic Pain Treatment Of Breast Cancer Colorectal Cancer Cytokine Acute Pain Morphinans Constipation Neuropathic Pain Treatment Of Chronic Pain Anti Infectives Pegylation Metastatic Colorectal Cancer Aminoglycoside Metastatic Breast Cancer Nektar Therapeutics Opioid Antagonists Opioid Induced Constipation Pneumonia

Is NKTR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.928
52 Week Low 0.4126
Average Volume 1,078,595
200-Day Moving Average 1.19
50-Day Moving Average 1.28
20-Day Moving Average 1.33
10-Day Moving Average 1.32
Average True Range 0.08
RSI (14) 43.50
ADX 26.97
+DI 19.22
-DI 18.87
Chandelier Exit (Long, 3 ATRs) 1.24
Chandelier Exit (Short, 3 ATRs) 1.44
Upper Bollinger Bands 1.47
Lower Bollinger Band 1.19
Percent B (%b) 0.14
BandWidth 20.73
MACD Line -0.01
MACD Signal Line 0.02
MACD Histogram -0.0225
Fundamentals Value
Market Cap 234.65 Million
Num Shares 191 Million
EPS -1.55
Price-to-Earnings (P/E) Ratio -0.79
Price-to-Sales 1.53
Price-to-Book 0.85
PEG Ratio 3.22
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.32
Resistance 3 (R3) 1.32 1.29 1.30
Resistance 2 (R2) 1.29 1.27 1.29 1.30
Resistance 1 (R1) 1.26 1.26 1.28 1.26 1.29
Pivot Point 1.23 1.23 1.24 1.23 1.23
Support 1 (S1) 1.20 1.21 1.22 1.20 1.17
Support 2 (S2) 1.18 1.20 1.18 1.16
Support 3 (S3) 1.15 1.18 1.16
Support 4 (S4) 1.14